Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study

S. S. Ramalingam,Suzanne E. Dahlberg,Corey J. Langer,Robert Gray,Chandra P. Belani,J. R. Brahmer,Alan Sandler,Joan H. Schiller,David H. Johnson

Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study

2007

S. S. Ramalingam
Suzanne E. Dahlberg
Corey J. Langer
Robert Gray
Chandra P. Belani
J. R. Brahmer
Alan Sandler
Joan H. Schiller
David H. Johnson

7535 Background: PC administered in combination with bevacizumab extends survival for advanced non-squamous NSCLC pts. Based on SEER data, elderly pts (age ≥70 years) represent >50% of all new case...

Keywords:

non-small cell lung cancer (NSCLC)
Bevacizumab
Carboplatin
Paclitaxel
Oncology
Medicine
Internal medicine
seer data
advanced stage

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations